HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population
HELIOS China Registry: A Prospective, Single-arm, Multicenter Study to Evaluate the HELIOS Biodegradable Polymer Sirolimus-eluting Stent in a 'Real-World' Patient Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Liu, MD, PhD
- Phone Number: 18602973275
- Email: 1391643423@qq.com
Study Contact Backup
- Name: Ruining Zhang, MS
- Phone Number: 86-029-84775183
- Email: liuyimeishan@hotmail.com
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China, 710054
- Recruiting
- Ling Tao
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1)18-85 years old, male or non-pregnancy female; 2)Patients with coronary artery disease who match the indication of stent implantation; 3)Patients who can understand the nature of the study, agree to participate and accept clinical follow-up
Exclusion Criteria:
- Patients who can not tolerate the material or medication in this study; Pregnancy or lactation women
- Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;
- Patients are, in the opinion of the investigator, unable to comply with the requirements of the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional group
HELIOS biodegradable polymer sirolimus-eluting stents
|
HELIOS biodegradable polymer sirolimus-eluting stents
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
target lesion failure (TLF)
Time Frame: 12 months
|
a composite endpoint of cardiac death, target lesion related myocardial infarction, and/or target lesion revascularization
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient oriented composite endpoint
Time Frame: 1、6、12、36、60 months
|
a composite endpoint of all cause death, all myocardial infarction and all revascularization
|
1、6、12、36、60 months
|
|
all cause death
Time Frame: 1、6、12、36、60 months
|
including cardiac and non-cardiac death
|
1、6、12、36、60 months
|
|
cardiac death
Time Frame: 1、6、12、36、60 months
|
death from cardiac cause
|
1、6、12、36、60 months
|
|
Myocardial infarction
Time Frame: 1、6、12、36、60 months
|
All myocardial infarction (MI) data were reported based on extended historical definitions.MI was always considered a target vessel, unless there was documented proof that the infarction arose from the nontreated coronary artery.
|
1、6、12、36、60 months
|
|
Stent thrombosis
Time Frame: 1、6、12、36、60 months
|
Stent thrombosis (ST) was defined according to Academic Research Consortium criteria
|
1、6、12、36、60 months
|
|
target lesion revascularization
Time Frame: 1、6、12、36、60 months
|
TLR was defined as any repeat revascularization by PCI or CABG
|
1、6、12、36、60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Ling Tao, MD, PhD, First Affiliated Hospital,Fourth Military Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
Other Study ID Numbers
- ky20182050-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.